Wall Street Zen Upgrades Pharming Group (NASDAQ:PHAR) to Hold

Pharming Group (NASDAQ:PHAR) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

PHAR has been the subject of several other reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Pharming Group in a report on Friday, August 7th. Oppenheimer reissued an “outperform” rating on shares of Pharming Group in a report on Thursday, July 30th. Zacks Research cut Pharming Group from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Canaccord Genuity Group set a $38.00 target price on Pharming Group in a research report on Wednesday, September 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research note on Tuesday, September 22nd. Three investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, Pharming Group has an average rating of “Hold” and a consensus price target of $38.67.

Pharming Group Stock Performance

Shares of PHAR opened at $11.20 on Friday. The firm has a 50-day moving average price of $10.67 and a 200 day moving average price of $12.59. The firm has a market capitalization of $792.74 million, a PE ratio of 93.33 and a beta of -0.05. The company has a quick ratio of 2.31, a current ratio of 3.01 and a debt-to-equity ratio of 0.34. Pharming Group has a 52-week low of $9.11 and a 52-week high of $21.34.

Pharming Group (NASDAQ:PHAR) last released its earnings results on Thursday, July 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. On average, sell-side analysts anticipate that Pharming Group will post 0.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP acquired a new position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group comprises approximately 6.0% of MAC Alpha Capital Management LP’s investment portfolio, making the stock its 2nd largest holding. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.